Lead author of the ATTRibute-CM trial says it was "robustly positive," and shows "the tantalizing possibility of genuine clinical improvements" for this progressive and fatal condition.
Results also presented during late-breaking session at ESC Heart Failure congress 2023 ZURICH, SWITZERLAND, May 22, 2023 - (ACN Newswire) - Neurimmune announced today that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant .
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.